

1 **Seroprevalence, correlates and kinetics of SARS-CoV-2 Nucleocapsid**
2 **IgG antibody in healthcare workers at a tertiary hospital: A prevaccine**
3 **census study**

Daniel Maina^{1*}, Geoffrey Omuse¹, George Ong'ete², Patrick Mugaine¹, Shahin Sayed¹, Zahir Moloo^{1,3}, Reena Shah⁴, Anthony Etyang⁵, Rodney Adam^{1,4}

¹ Department of Pathology & Laboratory Medicine, Aga Khan University Hospital, Nairobi

² Occupational Safety & Health, Aga Khan University Hospital, Nairobi

³ Aga Khan Health Services

⁴ Department of Internal Medicine, Aga Khan University Hospital Nairobi

⁵ KEMRI–Wellcome Trust Research Programme, Kilifi, Kenya

*Corresponding author

Email: daniel.maina@aku.edu

4
5
6
7
8
9
10
11
12
13

14
15
16
17
18
19
20
21
22
23
24
25

26 **Abstract**

27 **Background:** Healthcare workers are perceived to be a high-risk group for acquiring SAR-CoV-2
28 infection, and more so in countries where COVID-19 vaccination uptake is low. Serosurveillance
29 may best determine the true extent of SARS-CoV-2 infection since most infected HCWs may be
30 asymptomatic or present with only mild symptoms. Over time, determining the true extent of
31 SARS-CoV-2 infection could inform hospital management and staff whether the preventive
32 measures instituted are effective and valuable in developing targeted solutions.

33 **Methods:** This was a census survey study conducted at the Aga Khan University Hospital,
34 Nairobi, between November 2020 and February 2021 before the implementation of the COVID-
35 19 vaccination. The SARS-CoV-2 nucleocapsid IgG test was performed using a chemiluminescent
36 assay.

37 **Results:** One thousand six hundred thirty-one (1631) staff enrolled, totalling 60% of the
38 workforce. The overall crude seroprevalence was 18.4% and the adjusted value (for assay
39 sensitivity of 86%) was 21.4% (95% CI; 19.2-23.7). The HCW groups with higher prevalence
40 included pharmacy (25.6%), outreach (24%), hospital- based nursing (22.2%) and catering staff
41 (22.6%). Independent predictors of a positive IgG result included prior COVID-19 like symptoms,
42 odds ratio (OR) 1.9 [95% confidence interval (CI) 1.3-2.9, p=0.002], and a prior positive SARS-
43 CoV-2 PCR result OR 11.0 (CI: 7.2-18.0, p<0.001). Age, sex, comorbidities or working in a COVID-
44 19 designated area were not associated with seropositivity. The odds of testing positive for IgG
45 after a positive PCR test were lowest if the antibody test was performed more than 2 months
46 later; OR 0.7 (CI: 0.48-0.95, p= 0.025).

47 **Conclusions:** The prevalence of anti- SARS-CoV-2 nucleocapsid IgG among HCWs was lower
48 than in the general population. Staff working in clinical areas were not at increased risk when
49 compared to staff working in non-clinical areas.

50
51
52
53
54
55
56
57
58
59

Introduction

60
61 SARS-CoV-2 infection remains a threat to public health, especially in low resource
62 settings where vaccine coverage remains low. As of 2nd March 2022, only 13.9% of the Kenyan
63 population was fully vaccinated (1). The positivity rate with PCR testing in the general
64 population continues to fluctuate and was less than 1% at the start of March 2022. Admissions
65 to hospitals reflect this fluctuation. Data on the infection rates of healthcare staff in Kenya are
66 scanty and often do not include details of exposure risk.

67 The country had 7,466 infected healthcare workers (HCWs) reported as of September
68 2021. Etyang et al. reported seroprevalences of 43.8% (urban), 12.6% (rural) and 11.5% (rural)
69 in three counties in Kenya (2). The challenges facing HCW on the continent include inadequate
70 personal protective equipment (PPE) and limited SARS-CoV-2 testing of populations that seek
71 medical care, which leaves workers vulnerable (3), as was especially true before the provision
72 of SARS-CoV-2 vaccination to HCW.

73 Although infections in HCWs are often attributed to occupational exposure, that is not
74 always the case. At Aga Khan University Hospital Nairobi (AKUHN), personal protective
75 equipment (PPE) appropriate for the level of clinical care has been routinely provided since the
76 beginning of the Kenyan outbreak. In addition, routine tests of admitted patients were
77 implemented. Therefore, we wished to know the level of risk to HCWs where PPE and testing
78 are readily available.

79 Although liberal PCR testing of HCWs has been done at AKUHN throughout the
80 outbreak, asymptomatic HCWs were not routinely tested. Since asymptomatic infections have
81 comprised a significant percentage of infections in some series, it is possible that a significant

82 number of staff infections have been missed (4). The serosurvey helped address the suitability
83 of our approaches to staff safety.

84

85 **Materials and Methods**

86 This research was a census study in which all HCW at AKUHN were eligible to
87 participate. The staff were sensitised about the study through posters, institutional email
88 addresses and group talks. One thousand, six hundred thirty-one staff consented and were
89 recruited in the study (>60% of the workforce). The study lasted from November 2020 to
90 February 2021, before the implementation of COVID-19 vaccination in the hospital.

91 Staff were categorised into five groups based on the perceived risk of COVID-19
92 exposure at the workplace:

- 93 ❖ Clinical COVID-19 areas: COVID-19 isolation wards, Intensive Care Unit (ICU), High
94 Dependence Unit (HDU), Accident and Emergency (A&E) triage
- 95 ❖ Non-COVID-19 clinical areas: general wards, outpatient clinics
- 96 ❖ Allied health: laboratory, radiology, pharmacy
- 97 ❖ Support staff: catering, facilities, housekeeping
- 98 ❖ Academic/Administration areas

99

100 *Specimen collection & assay*

101 A phlebotomist collected 5-10 ml of blood in a serum separator vacutainer (Greiner Bio-
102 One GmbH – Germany) from each participant. In all cases, blood samples were labelled with a
103 unique study identifier, centrifuged and serum separated within 24 hours of collection.

104

105 *Laboratory testing*

106 The antibody test was performed using a chemiluminescent assay (Abbott, USA),
107 according to the manufacturer's instructions and standard operating procedures. The Abbott
108 qualitative anti-nucleocapsid CoV-2 IgG assay for SARS has a manufacturer's stated sensitivity of
109 100% 14 days after the onset of symptoms and a specificity of 99.6%. Our laboratory evaluation
110 using 54 samples from known COVID-19 patients showed a sensitivity of 86%, 14 days after the
111 onset of symptoms, and a specificity of 100% using 20 samples before COVID-19 (unpublished
112 data). An independent evaluation of this kit by Public Health England reported a sensitivity of
113 93.9% for samples ≥ 14 days post-symptom onset of symptoms and a specificity of 100% (5).
114 The default result unit for the SARS-CoV-2 IgG assay is Index (S/C), with a cutoff of 1.40.
115 This study was conducted according to the criteria set by the declaration of Helsinki on Human
116 research. The protocol was approved by the Ethics Review Committee of Aga Khan University
117 Nairobi (Ref: 2020/IERC-129 v4).
118 Written informed consent was obtained from all participants.

119

120 *Data collection and Analysis*

121 Stata 16 (StataCorp, Texas, USA) was used to perform the statistical analysis.
122 The demographic and risk details of the patients were captured by filling in a guided
123 questionnaire. Descriptive statistics are presented as medians [interquartile range (IQR)] or
124 means (standard deviation, SD) and percentages (proportions), where appropriate. Crude
125 seroprevalence figures were adjusted for the performance (sensitivity 86%, specificity 100%) of
126 the nucleocapsid assay in our evaluation (6),.

127 Risks (associations) were analysed using logistic regression analyses and chi-square
128 statistics, presented here, respectively, as odds ratio (OR) with 95% confidence interval (95% CI)
129 and chi statistics with p-value.

130 Antibody kinetics were evaluated for participants with documented SARS-CoV-2 PCR
131 results and compared with the proportions of HCWs with positive IgG at different time points
132 between the PCR and antibody tests.

133

134 **Results**

135 One thousand six hundred thirty-one (1,631) staff members, both AKUHN and
136 contracted employees, participated in the study. This figure represented 60% of the hospital
137 workforce. The median age was 35 years (interquartile range 30-45). AKUHN employees
138 comprised 86.7% of the study participants. Males made up 44% of the tested staff, and the
139 overall crude seroprevalence of SARS-CoV-2 in the study was 18.4%, adjusted to 21.4% (95% CI;
140 19.2-23.7).

141 The seroprevalence among AKUHN staff (22.0%) was not significantly different from that
142 of contracted workers (17.7%) (p-value = 0.193). The proportion of staff with SARS-CoV-2
143 antibodies varied between the different cadres within these two broad groups. Notable cadres
144 with higher proportions of exposed personnel included pharmacy (25.6%), outreach (24%),
145 nursing (22.2%) and catering (22.6%), as shown in Table 1.

146

147

148

149

150
151

Table 1: SARS-CoV-2 anti- nucleocapsid IgG antibody prevalence in HCWs

	Total	Seropositive n (crude prevalence)	Adjusted Prevalence (95% confidence interval)
All	1631	300 (18.4%)	21.4 (19.2-23.7)
Males	716	126 (17.6%)	20.5 (17.4-24.0)
Females	915	174 (19.0%)	22.1 (19.3-25.2)
Age			
20-29	368	72 (19.6%)	22.8% (18.4-27.8)
30-39	666	124 (18.6%)	21.6% (18.4-26.2)
40-49	392	72 (18.4%)	21.4% (17.2-25.0)
50-59	145	27 (18.6%)	21.6% (15.2-30.0)
≥60	45	3 (6.7%)	7.8% (2.5-21.8)
Symptomatic (preceding 3 months)			
Yes	750	189 (25.2%)	29.3% (26.1-32.7)
No	881	111 (12.6%)	14.7% (12.4-17.2)
AKU Staff	1414	267 (18.9%)	22.0% (19.8-24.4)
Contracted Staff	217	33 (15.2%)	17.7% (12.8-24.0)
AKUHN Divisions			
Nursing	347	77 (22.2%)	25.8 (21.0-31.3)
Pharmacy	43	11 (25.6%)	29.8 (14.8-40.6)
Outreach	117	28 (24.0%)	27.9 (19.9-37.8)
Pathology	84	14 (16.7%)	19.4 (11.7-30.5)
Diagnostic imaging	53	9 (17.0%)	19.8 (10.6-34.3)
Medical services	466	78 (16.7%)	19.4 (15.7-23.7)
Others (nonclinical)	304	57 (18.8%)	21.9 (16.9-27.4)
Risk Based			
Clinical Covid	209	49 (23.4%)	27.2 (21.2-34.5)
Non-Covid Clinical	530	99 (18.7%)	21.7 (18.1-25.9)
Allied health	234	37 (15.8%)	18.4 (13.6-24.5)
Support	185	35 (18.9%)	22.0 (16.2-29.3)
Admin/Academic	249	46 (18.5%)	21.5 (16.4-27.7)
Contracted staff			
Catering	53	12 (22.6%)	26.3 (14.3-42.1)
Housekeeping	103	14 (13.6%)	15.8 (8.8-25.3)
Security	35	4 (11.4%)	13.3 (3.7-31.0)

Others	26	3 (11.5%)	13.4 (2.9-35.1)
--------	----	-----------	-----------------

152 **Key:** Clinical Covid: isolation wards, ICU, HDU, A&E triage; Clinical non-Covid: general wards, outpatient clinics;
153 Allied health: laboratory, radiology, pharmacy; Support staff: catering, facilities, housekeeping;
154 Academic/Administration: nonclinical faculty, administrative staff

155

156 Seven hundred sixty-nine HCW (47%) had taken a SARS-CoV-2 PCR test prior to the
157 study, with 136 (18%) confirmed positive. Seroprevalence was 66.2% among HCWs with a
158 positive PCR test and 13.5 % among those with a negative result ($p < 0.001$). Slightly less than
159 half (46%) of the 1631 HCW reported symptoms consistent with COVID-19 in the previous 3
160 months prior to the study. The most prevalent symptoms were headache (52%), sneezing
161 (51%), cough (42%) and fever (16%). Adjusted seroprevalence among symptomatic and
162 asymptomatic HCWs was 29.3% and 14.7%, respectively ($p < 0.001$).

163

164 **Predictors of a positive anti-SARS-CoV-2 nucleocapsid IgG test**

165 Having previously tested for COVID-19 (PCR) irrespective of test result increased the
166 odds of testing positive with the antibody test, OR 1.7 (95% CI: 1.3-2.2, $p < 0.001$) (Table 2). The
167 odds were even higher in those who had tested positive with PCR (OR 12.5 95% CI: 8.2-19.1,
168 $p < 0.001$). This also applied to those who had experienced flu-like symptoms in the previous 3
169 months prior to enrollment in the study, OR 2.3 (95% CI 1.8-3.0, $p < 0.001$); antibody test
170 performed 2-4 weeks after the PCR test, OR 1.6 (95% CI 1.02-2.54, $p = 0.041$); or reported daily
171 contact with COVID-19 patients, OR 1.5 (95% CI 1.2-2.0, $p = 0.002$).

172 Univariate analysis of specific symptoms showed a significant association between cough,
173 headache, fever, coryza and loss of smell with the positive Covid-IgG test. However,

174 multivariate analysis revealed an independent association with only cough, fever and loss of
 175 smell.

176

177 **Table 2: Risk factors for a positive anti-nucleocapsid IgG result**

	SARS-CoV-2 IgG Positive n (%)	Odds Ratio (95% CI)	p-value
Previously tested for SARS-CoV-2 (PCR)			
Yes	175 (22.8)	1.7 (1.3-2.2)	<0.001
No	124 (14.5)		
Time interval between PCR and serology test			
<2 weeks	25 (23.6)	1.1 (0.6-1.7)	0.855
2-4 weeks	32 (30.8)	1.6 (1.02-2.54)	0.041
1-2 months	37 (25.7)	1.2 (0.8-1.8)	0.375
>2 months	80 (19.7)	0.7 (0.48-0.95)	0.025
COVID-19 PCR result			
Positive	90 (66.2)	12.5 (8.2-19.1)	<0.001
Negative	85 (13.5)		
Flu-like symptoms past 3 months			
Yes	189 (25.2)	2.3 (1.8-3.0)	<0.001
No	111 (12.6)		
Univariate analysis of individual symptoms			
Cough	93 (29.6)	2.3 (1.7-3.0)	<0.001
Sneezing	92 (24.2)	1.6 (1.2-2.1)	0.001
Fever	50 (42.4)	3.7 (2.5-5.5)	<0.001
Running nose	87 (24)	1.6 (1.2-2.1)	0.002
Chest pain	29 (26.6)	1.7 (1.1-2.6)	0.023
Headache	102 (26)	1.8 (1.4-2.4)	<0.001
Loss of smell	59 (67.8)	11.4 (7.1-18.2)	<0.001
Multivariate analysis symptoms		Adjusted OR	

Cough		1.7 (1.2-2.4)	0.004
Fever		1.7 (1.1-2.8)	0.026
Loss of smell		8.6 (5.2-14.3)	<0.001
Household contacts or workmates diagnosed with covid			
Yes	163 (19.6)	1.2 (0.9-1.5)	0.220
No	137 (17.2)		
Work involves frequent (daily) close contact with COVID-19 patients			
Yes	190 (21.1)	1.5 (1.2-2.0)	0.002
No	110 (15.1)		
Hospital Location Risk (clinical COVID)			
Yes	49 (22)	1.3 (0.9-1.8)	0.171
No	251 (18)		

178

179 Age, sex, and comorbidities (diabetes and hypertension) were not risk factors for a
 180 positive SARS-CoV-2 IgG test .

181 A binomial logistic regression was run to understand the effects of a positive COVID-19
 182 PCR result, flu-like symptoms 3 months prior to testing, working in close contact with COVID-19
 183 patients and antibody test performed 2-4 weeks after PCR test on the likelihood of being
 184 seropositive. A positive PCR result and flu-like symptoms predicted seropositivity. However,
 185 interacting daily with COVID-19 patients and the time interval between PCR and antibody tests
 186 did not achieve statistical significance (Table3).

187

188

189

190 **Table 3: Predictors of a positive anti-nucleocapsid IgG result**

	Univariate		Multivariate Model ^a	
	Odds Ratio (95% CI)	p-value	Odds Ratio (95% CI)	p-value
SARS-CoV-2 PCR result +	12.5 (8.2-19.1)	<0.001	11.0 (7.2-17.0)	<0.001
Flu-like symptoms past 3 months	2.32 (1.8-3.0)	<0.001	1.9 (1.3-2.9)	0.002
Work involves frequent (daily) close contact with COVID-19 patients	1.5 (1.2-2.0)	0.002	1.3 (0.8-1.8)	0.267
Time interval (2-4 weeks) Between PCR and antibody test	1.6 (1.02-2.54)	0.041	1.2 (0.7-2.1)	0.450

191
 192 ^aModel includes risk factors with p< 0.10 on univariate analysis: positive SARS-CoV-2 PCR result,
 193 presence of flu-like symptoms, frequent close contact with COVID-19 patients at the workplace and time
 194 between the PCR and antibody test
 195

196 *COVID-19 IgG dynamics*

197 The seroprevalence in participants who tested positive for SARS-CoV-2 by PCR peaked 1-
 198 2 months following the PCR test and sharply declined thereafter (Figs 1&2). The odds of testing
 199 antibody positive were lowest if performed more than 2 months after PCR, OR 0.7 (CI 0.48-
 200 0.95). The PCR negative group had a steady but slow decline in seroprevalence throughout the
 201 same period.

202 **Fig 1. Proportion of HCWs with positive antibody over time after PCR test**

203

204 **Fig 2. Antibody index at various time points post-SARS-CoV-2-19 PCR+ test**

205 Key: The dashed horizontal line is the assay cutoff point (1.4)

206

207 **Discussion**

208 We determined the seroprevalence and kinetics of SARS-CoV2 nucleocapsid IgG
209 antibodies in HCW prior to the advent of the COVID-19 vaccine when little information was
210 available on the clinical implications (immunity) of seroconverting. This was also before any
211 variant of concern had been reported in the country. The adjusted seroprevalence of 21% was
212 well below any reported in a public urban hospital (43.8%) in Nairobi (2). Whether the strict
213 COVID-19 prevention measures enforced early in AKUHN contributed substantially to the
214 relatively lower seroprevalence has not been determined. Hospitals in rural areas had lower
215 rates reflecting low community transmission (2). Early in the COVID-19 pandemic, Nairobi was
216 the epicentre of the infection, which later spread to other parts of the country.

217 Elsewhere on the continent, seroprevalence among HCW ranged from 0% to 45.1%,
218 with the highest prevalence in Nigeria (7).

219 Contrary to previous assumptions, there was no significant difference in seroprevalence
220 between frontline staff (high-risk work-based exposure) and staff working in nonclinical areas
221 (low-risk work exposure), suggesting that most of the SARS-CoV-2 infections occurred in the
222 community. During the same period, a study conducted in India reported similar figures
223 between HCWs and the general public (25.6% versus 23.2%) (8). Here in Kenya, a study
224 reported a higher prevalence (61.8%) among blood donors than the prevailing seroprevalence
225 among HCWs in Nairobi for the period January through March 2021(9), reflecting the high
226 community transmission prevalent during the study period.

227 The seroprevalence across the age groups was similar for HCW under 60 years of age
228 and then decreased for age ≥ 60 . Some studies have found increased seropositivity with
229 increasing age for some age brackets (10, 11). Pharmacy and catering staff had the highest

230 prevalence, possibly explained by confined working spaces with close contact between the staff
231 in the two areas.

232 Testing positive for SARS-CoV-2 by PCR and having flu-like symptoms independently
233 predicted a positive SARS-CoV-2 antibody result. The three symptoms that independently
234 predicted a positive antibody result were loss of smell, followed by fever and cough (adjusted
235 OR 8.7, 1.7, 1.7, respectively). Other studies have reported similar symptoms among HCWs
236 elsewhere (12, 13).

237 Symptomatic staff had mild COVID-19 disease, none of which required hospitalisation.
238 The hospital workforce is relatively young (mean age of 37 years) and has few comorbidities,
239 which could partly explain the mild COVID-19 disease seen in the facility.

240 Correct interpretation of serology test results requires a proper understanding of the
241 antibody dynamics, as demonstrated in our findings. Testing for nucleocapsid IgG antibodies
242 three months after SARS-CoV-2 infection is likely to miss a significant proportion of exposed
243 people. Only 20% of HCW with confirmed infection in our study were positive for IgG antibodies
244 at three months and beyond. Van Elslande et al. reported that anti-nucleocapsid IgG antibody
245 levels of SARS-CoV-2 steadily decreased after 2 months up to 8 months after PCR, while another
246 study showed a decline in positivity starting at 6 months onward after the onset of COVID-19
247 symptoms or testing (14, 15).

248 All participants in our study had mild disease or were asymptomatic and the kinetics
249 described here may not apply to those with severe COVID-19 disease, which has been
250 associated with earlier and higher antibody levels compared with asymptomatic infections (16,
251 17).

252

253 **Conclusions**

254 The prevalence of anti- SARS-CoV-2 nucleocapsid IgG among HCWs was high but lower
255 than in the general population. There were no statistically significant differences in
256 seroprevalence between the clinical areas and the rest of the hospital. Independent predictors
257 of a seropositive result were a positive SARS-CoV-2 PCR result and flu-like symptoms in the 3
258 months prior to joining the study. Seropositivity peaked 2 months after a positive PCR test and
259 then declined.

260

261 **Acknowledgements:**

262 Much appreciation to the administration of AKUHN for facilitating the study. Thanks to Cyrus Matheka,
263 David Kawalya and Assumpta Chege for the logistical assistance.

264

265 **References:**

266

- 267 1. Coronavirus (COVID-19) Vaccinations 2022 [Available from: [https://ourworldindata.org/covid-](https://ourworldindata.org/covid-vaccinations)
268 [vaccinations](https://ourworldindata.org/covid-vaccinations)].
- 269 2. Etyang AO, Lucinde R, Karanja H, Kalu C, Mugo D, Nyagwange J, et al. Seroprevalence of Antibodies
270 to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya. *Clinical*
271 *Infectious Diseases*. 2021.
- 272 3. WHO. COVID-19 WHO African Region: External situation report 12. 2020.
- 273 4. Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S, et al. Screening of healthcare
274 workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. *Elife*.
275 2020;9:e58728.
- 276 5. England PH. Evaluation of the Abbott SARS-CoV-2 IgG for the detection of anti-SARSCoV-2
277 antibodies.; June 2020.
- 278 6. Sempos CT, Tian L. Adjusting coronavirus prevalence estimates for laboratory test kit error.
279 *American journal of epidemiology*. 2021;190(1):109-15.

- 280 7. Müller SA, Wood RR, Hanefeld J, El-Bcheraoui C. Seroprevalence and Risk Factors of COVID-19 in
281 Healthcare Workers From Eleven African Countries: A Scoping Review and Appraisal of Existing
282 Evidence. *Health policy and planning*. 2021.
- 283 8. Murhekar MV, Bhatnagar T, Thangaraj JWV, Saravanakumar V, Kumar MS, Selvaraju S, et al. SARS-
284 CoV-2 seroprevalence among the general population and healthcare workers in India, December
285 2020–January 2021. *International Journal of Infectious Diseases*. 2021;108:145-55.
- 286 9. Uyoga S, Adetifa IM, Otiende M, Yegon C, Agweyu A, Warimwe GM, et al. Prevalence of SARS-CoV-2
287 antibodies from a national serosurveillance of Kenyan blood donors, January-March 2021. *JAMA*.
288 2021;326(14):1436-8.
- 289 10. Mostafa A, Kandil S, El-Sayed MH, Girgis S, Hafez H, Yosef M, et al. SARS-CoV-2 seroconversion
290 among 4040 Egyptian healthcare workers in 12 resource-limited healthcare facilities: A prospective
291 cohort study. *International Journal of Infectious Diseases*. 2021;104:534-42.
- 292 11. Prakash O, Solanki B, Sheth J, Makwana G, Kadam M, Vyas S, et al. SARS-CoV2 IgG antibody:
293 Seroprevalence among health care workers. *Clinical epidemiology and global health*.
294 2021;11:100766.
- 295 12. Magnavita N, Tripepi G, Di Prinzio RR. Symptoms in health care workers during the COVID-19
296 epidemic. A cross-sectional survey. *International journal of environmental research and public
297 health*. 2020;17(14):5218.
- 298 13. Gholami M, Fawad I, Shadan S, Rowaiee R, Ghanem H, Khamis AH, et al. COVID-19 and healthcare
299 workers: A systematic review and meta-analysis. *International Journal of Infectious Diseases*.
300 2021;104:335-46.
- 301 14. Van Elslande J, Oyaert M, Ailliet S, Van Ranst M, Lorent N, Weygaerde YV et al. Longitudinal follow-
302 up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after
303 infection. *Journal of Clinical Virology*. 2021;136:104765.
- 304 15. Chansaenroj J, Yorsaeng R, Posuwan N, Puenpa J, Wanlapakorn N, Sudhinaraset N, et al. Long-term
305 specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients. *Scientific
306 reports*. 2021;11(1):1-8.
- 307 16. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of
308 novel coronavirus disease 2019. *Clinical Infectious Diseases*. 2020.
- 309 17. Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J et al. Different longitudinal patterns of nucleic acid
310 and serology testing results based on disease severity of COVID-19 patients. *Emerging microbes &
311 infections*. 2020;9(1):833-6.

312

Anti-SARS-CoV2 nucleocapsid IgG dynamics




Fig 1




Fig 2